Characterization and evaluation of enteric-coated controlled release tablet formulations of diclofenac sodium

Acta Pharmaceutica

Volumn 46, Issue 4, 1996, Pages 285-294

  Rafiee Tehrant, Morteza ^a   Hatefi, Arash ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

air suspension; diclofenac sodium; dissolution; enteric coating; triethylcitrate

Indexed keywords

CALCIUM SULFATE; CITRIC ACID TRIETHYL ESTER; DICLOFENAC; ETHYL CELLULOSE; EUDRAGIT; EUDRAGIT RS; LACTOSE;

ARTICLE; DRUG FORMULATION; DRUG GRANULATION; DRUG RELEASE; DRUG SOLUBILITY; ENTERIC COATED TABLET; SUSTAINED RELEASE PREPARATION;

EID: 0030478518     PISSN: 13300075     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. S. Y. Lin and Y. H. Kao, Pharm. Res. 8 (1991) 919.
2. S. I. Saleh, S. H. Khider, J. M. Aiache, E. Beyssac, and R. Camacho, S. T. P. Pharma Sci. 2 (1992) 242.
3. C. H. Liu, Y. H. Kao, S. C. Chen, T. D. Sokoloski, and M. T. Sheu, J. Pharm. Pharmacol. 47 (1995) 360.
4. V. D. Vilivalam and C. M. Adeyeye, J. Microencaps. 11 (1994) 455.
5. A. Navarro and M. P. Ballesteros, S. T. P. Pharma Pratiques 4 (1994) 108.
6. J. P. Famacy and H. E. Paulus, Therapeutic Applications of Nsaids, Marcel Dekker, New York 1992, 394.
7. W. M. O'Brien, Amer. J. Med. 80 (Suppl. 4B) (1986) 70.
8. F. Acarturk, Pharmazie 44 (1989) 621.
9. E. Nelson, Clin. Pharm. Ther. 4 (1963) 283.
10. J. R. Leonards and G. Levy, JAMA 193 (1965) 99.
11. M. Rafiee-Tehrani and N. Sadegh-Shobeiri, Drug Dev. Ind. Pharm. 21 (1995) 1193.
12. B. Sa, ibid. 17 (1991) 893.
13. B. Lindstedt, M. Sjoberg, and J. Hjartstam, Int. J. Pharm. 67 (1991) 21.
14. M. Hasan, N. Najib, M. Suleiman, Y. El-Sayed, and M. Abdel-Hamid, Drug Dev. Ind. Pharm. 18 (1992) 1981.
15. Y. Hirotani, Y. Arakawa, Y. Maeda, A. Yamaji, A. Kamada, and T. Nishihata, Chem. Pharm. Bull. 35 (1987) 3049.
16. M. T. Sheu, H. L. Chou, C. C. Kao, C. H. Liu, and T. D. Sokoloski, Int. J. Pharm. 85 (1992) 57.
17. S. Y. Lin, C. L. Cheng, and P. C. Lin, Pharm. World Sci. 17 (1995) 42.
18. F. Acarturk, Pharmazie 44 (1989) 547.
19. T. Nishihata, Int. J. Pharm. 40 (1987) 125.
20. J. C. Bain, S. B. Tan, D. Ganderton, and M. C. Solomon, Drug Dev. Ind. Pharm. 17 (1991) 215.
21. WHO Guidelines on Stability Testing of Pharmaceutical Products Containing Well-established Drug Substances in Conventional Dosage Forms, WHO, Geneve 1993, 7.
22. W. Grimm and K. Krummen, Stability Testing in the EC, Japan and the USA, Wissenschaftliche Verlagsgesselschaft, Stuttgart 1993, 173.
23. K. Lehmann, in Aqueous Polymeric Coatings for Pharmaceutical Dosage Forms (Ed. J. W. McGinity), Marcel Dekker, New York 1989, 153.
24. C. R. Steuernagel, ibid., 1.
25. M. Rafiee-Tehrani and T. Haddad, Eur. J. Pharm. Biopharm. 39 (1993) 87.
26. M. Rafiee-Tehrani and Z. Jafari-Azar, Eur. J. Pharm. Sci , submitted for publication.
27. K. Lehmann and D. Dreher, J. Pharm. Tech. Prod. Manuf. 2 (1981) 31.
28. P. G. Welling, Clin. Pharmacokin. 9 (1984) 404.
29. A. Yocobi and E. Halperin-Walega, Oral Sustained Release Formulations, Pergamon, New York 1988, 125.
30. U. V. Banakar, Pharmaceutical Dissolution Testing, Marcel Dekker, New York 1992, 211.
31. S. C. Chattaraj and S. K. Das, Drug Dev. Ind. Pharm. 16 (1990) 283.
32. A. A. Abdel Rahman, E. M. Samy, S. I. Abdel Rahman, A. E. Aboutaleb, and A. Stamm, Eur. J. Pharm. Biopharm. 38 (1992) 71.
33. K. Amighi and A. Moes, ibid. 42 (1996) 29.